-
Document de presse | 2005.10.12
Institut Pasteur and Total join forces to combat infectious diseases
On October 13, Total and Institut Pasteur signed a corporate funding agreement intended to strengthen the scientific and human resources allocated to the fight against infectious diseases, especially sexually transmitted diseases (STD). The five-year agreement covers two areas. Press release Paris, october 13, 2005 · Support for Institut Pasteur’s research...
-
Document de presse | 2005.06.27
Gates millions for vaccine research The fight against hepatitis C and HIV: foundation supports international consortium
The Bill and Melinda Gates Foundation (Seattle, USA) has decided to fund an international research consortium led by the German Research Centre of Biotechnology (GBF) in Braunschweig and the Institut Pasteur in Paris. The long-term goal of the 9 million dollar project is the development of vaccines against Hepatitis C and HIV. Press release Paris, june 28, 2005 “...
-
Document de presse | 2005.06.23
INRS–Institut Armand-Frappier (Canada) Joins the Réseau International des Instituts Pasteur And Supports Global Appeal to Boost Attention to Neglected Diseases
The INRS–Institut Armand-Frappier research centre, located in Laval, close to Montreal (Canada), recently joined the Réseau International des Instituts Pasteur (RIIP) which now has 29 member institutions on five continents. The INRS–Institut Armand-Frappier research centre is the first North American institution to join the RIIP network. Press release Paris, june 24,...
-
Document de presse | 2005.04.18
Newborn susceptibility to infection now deciphered
A joint Institut Pasteur-Inserm team has deciphered key mechanisms in the development of newborn immune systems. This study has made it possible to understand why infants are susceptible to early infections that cause high mortality rates, particularly in developing countries. Understanding these mechanisms offers possibilities for new types of treatment and vaccines adapted to protect newborns...
-
Document de presse | 2004.09.29
Procter & Gamble And Institut Pasteur Announce A Joint Collaboration To Develop A New Therapeutic Approach For Asthma
Procter & Gamble Pharmaceuticals (P&GP), a subsidiary of The Procter & Gamble Co. (NYSE: PG), and Institut Pasteur today announced an agreement under which P&GP will develop and seek market authorization for drug candidate EFD, a new type of immuno-modulator for the treatment of asthma and other allergic disorders, stemming from a joint research collaboration between Institut...
-
Document de presse | 2004.09.08
Human Genome: A New Mutagenic Phenomenon Revealed
Researchers from the Institut Pasteur associated with the CNRS have recently demonstrated the importance of the insertion of small sequences of mitochondrial DNA in the human genome (Public Library of Sciences, 7 September 2004). These insertions are potentially mutagenic and may be connected with serious pathologies. This research could enable the development of new diagnostic tools for cancer...
-
Article | 2017.03.16
Why support us?
The Institut Pasteur a non-profit foundation with recognized charitable status, is authorized to raise funds for its missions in the fields of research, public health and education. Your donations are directly given to the teams responsible for those missions – there's no intermediary.
-
Article | 2017.03.21
Apprenticeship tax
Giving your apprenticeship tax to the Institut Pasteur's Education Center means supporting advanced training for young scientists that will enable the medical discoveries of the future.
-
Article | 2017.03.27
Join Pasteurdon!
A national media eventEvery October, the Institut Pasteur organizes a fundraising weekend known as Pasteurdon to raise funds and awareness about its research among the general public.A number of companies are involved in this major fundraising event, alongside several television channels, 14 national radio stations, presenters and journalists, and a loyal patron: Alexandra Lamy.See the Pasteudon...
-
News | 2020.06.04
Study reveals conditions for the onset of severe forms of COVID-19
Using state-of-the-art sequencing and bioinformatics techniques, scientists from the Institut Pasteur, working with fellow scientists from Israel and China, determined that patients with severe forms of COVID-19 presented an abnormal, ineffective lymphocyte response and a massive infiltration of inflammatory cells in the lungs.Patients with COVID-19 (see the COVID-19 fact sheet)present a...